Authors: Sandra Link, Mark Schaub, Corporate & Commercial Group, King & Wood Mallesons

What is GSCA?

GSCA requires German companies to analyze and report compliance with certain human rights and environmental standards along their supply chain.

GSCA does not intend to implement German social standards world-wide but aims to ensure compliance within the supply chain with minimum international standards (i.e. no child labor or forced labor or meeting basic environmental protection requirements).
Continue Reading German Supply Chain Act (GSCA) – Implications for Chinese companies

Compared with Regulations on Supervision and Administration of Medical Devices (2017 Amendment) (the “2017 Edition of the Regulations”), the New Regulations pay more attention to promoting the innovative development of the medical device industry, and simultaneously focus on the quality and safety of medical device products. This article will interpret the main contents and the highlights of the amendment of the New Regulations, and analyze the changes in China’s medical device regulatory system under the New Regulations and its impact on the industry development.
Continue Reading Optimizing Supervision System and Promoting Industrial Development – Interpretation of Key Points of Regulations on Supervision and Administration of Medical Devices (2021 Amendment)

The Cyberspace Administration of China (CAC) issued a notice at 12:00 a.m. on 10 July 2021 to publicly solicit comments on the Cybersecurity Review Measures (Revised Draft for Comment)(the “Draft for Comment”) (for previous interpretations of the Cybersecurity Review Measures, please see the article: Innovations and Changes of Cybersecurity Review Measures). Considering the recent regulatory measures taken by CAC, the Cyber Security Review Office and other regulators on a number of enterprises, this article will address some of the key points of the Draft for Comment for your reference.
Continue Reading Q&A of Cybersecurity Review Measures (Revised Draft for Comment)

This article aims to present Chinese laws, rules and principles related to cross-border investigations, and to help enterprises to better understand, from a Chinese law perspective, the legal framework and respond appropriately when facing investigations conducted by foreign governments.
Continue Reading China is enhancing regulations on Cross-Border Investigations

With the recent pandemic and shifting political and economic conditions, Chinese companies, as they continue to grow internationally in size and stature, have had to deal with the complexities of managing an international conglomerate. Part of this has involved dealing with cross-border corporate misconduct across different jurisdictions. In this article, we share some practical guidance based on recent case experience on how to structure, plan and manage international white-collar offence investigations.
Continue Reading White-Collar Offences: Managing International Investigations

In China, once a patent for invention or utility model has been granted, apart from the patent invalidation proceeding, the patentee does not have other opportunities to amend any claim of the patent on his own initiative.  After the request for invalidation of the patent is filed, within one month after the patentee receives the request for invalidation and the evidence, the patentee is allowed to amend the claims of the patent at issue in response to the request for invalidation.  However, manners of amendment allowed are strictly limited.
Continue Reading Claim amendment in the patent invalidation proceeding